CLINICAL TRIALS AND OBSERVATIONS Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study
نویسندگان
چکیده
1Faculty of Medicine, Institute of Gynecology, Obstetrics, and Pediatrics, University of Copenhagen, Copenhagen, Denmark; 2Department of Pediatrics and 3The Cytogenetic Laboratory, The University Hospital Rigshospitalet, Copenhagen, Denmark; 4Department of Pediatrics, The University Hospital Linkjöping, Stockholm, Sweden; 5Department of Pediatrics, The University Hospital Umeå, Stockholm, Sweden; 6Department of Pediatrics, Aarhus University Hospital, Skejby, Denmark; 7Department of Pediatrics, Astrid Lindgrens Barnsjukhus, Stockholm, Sweden; 8Department of Pediatrics, University Hospital, Reykjavik, Iceland; 9Department of Pediatrics, University Hospital, Trondheim, Norway; 10Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark; 11Department of Pediatrics, University Hospital, Helsinki, Finland; and 12Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN
منابع مشابه
Clinical Trials and Observations: Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201
Pediatric Oncology Group (POG) protocol 9201 enrolled children with lesser-risk B-lineage acute lymphoblastic leukemia (ALL) defined by age (1-9), white blood cell count (WBC) less than 50 × 10 (50 000/μL), DNA findings of trisomies 4 and 10 (or DNA index > 1.16), and lack of overt central nervous system (CNS) leukemia. After vincristine, prednisone, and asparaginase induction, 650 of 653 eligi...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia
6-Mercaptopurine (6MP) and methotrexate are the backbone of continuation therapy for childhood acute lymphoblastic leukemia (ALL). In studies of oral 6MP and methotrexate, indices of chronic systemic exposure to active metabolites of these agents, namely, red blood cell (RBC) concentrations of methotrexate polyglutamates (MTXPGs) and thioguanine nucleotides (TGNs) have positively correlated wit...
متن کاملAcute lymphoblastic leukemia: an historical perspective.
See the related ASH 50th Anniversary Review articles under the ACUTE AND CHRONIC LEUKEMIAS section of the publication ASH 50th Anniversary Reviews: A Salute to the American Society of Hematology. Astute observations, dedicated researchers, cooperative groups, and clinical trials as well as guinea pig serum, hypoglycemic cows, and periwinkle plant extracts—all contributed to the evolution of the...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo
Methotrexate (MTX) and mercaptopurine (MP) are widely used antileukemic agents that inhibit de novo purine synthesis (DNPS) as a mechanism of their antileukemic effects. To elucidate pharmacodynamic differences among children with acute lymphoblastic leukemia (ALL), DNPS was measured in leukemic blasts from newly diagnosed patients before and after therapy with these agents. Patients were rando...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials
Although levels of minimal residual disease (MRD) decrease below the detection limit in most adult patients with standardrisk acute lymphoblastic leukemia (ALL) after consolidation treatment, about 30% of these patients will ultimately relapse. To evaluate the power of MRD monitoring as an indicator of impending relapse, we prospectively analyzed postconsolidation samples of 105 patients enroll...
متن کامل